Effect of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of prostate cancer patients

Brawley OW. Prostate cancer epidemiology in the United States. World J Urol, 2012, 30: 195–200.

Vijayalakshmi K, Vettriselvi V, Krishnan M, et al. Cytochrome p4501A1gene variants as susceptibility marker for prostate cancer. Cancer Biomark, 2005, 1: 251–258.

Anisimova NY, Sosnov AV, Ustyuzhanina NE, et al. Cytotoxic activity of peripheral blood mononuclear leukocytes, activated by interleukin-2/beta-cyclodextrin nanocomposition against androgen receptornegative prostate cancers. Oncology, 2011, 2011: 405656.

Kato T, Nakane K, Kojima T, et al. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression. Biochem Biophys Res Commun, 2012, 417: 966–971.

Dziedziejko V, Kurzawski M, Paczkowska E, et al. Association between IL-18 gene polymorphisms and the release of interleukin-18 from stimulated peripheral blood mononuclear cells. Postepy Hig Med Dosw, 2012, 66: 409–414.

Lebel-Binay S, Thiounn N, De Pinieux G, et al. IL-18 is produced by prostate cancer cells and secreted in responseto interferons. Int J Cancer, 2003, 106: 827–835.

Hikosaka S, Hara I, Miyake H, et al. Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model. Int J Urol, 2004, 11: 647–652.

Nong SJ, Wen DG, Fan CB, et al. Clinical value of Serum Interleukin-18 in patients with prostate cancer. Chinese-German J Clin Oncol, 2007, 6: 574–578.

Nong SJ, Zhang YP, Zhou SJ, et al. Relationship between serum IL-18 and VEGF levels in patients with prostate cancer. Chinese-German J Clin Oncol, 2010, 9: 643–647.

Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol, 2007, 4: 329–335.

Haghshenas MR, Hosseini SV, Mahmoudi M, et al. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol, 2009, 24: 1119–1122.

Yang J, Xu DL, Lu Q, et al. Prostate cancer risk and aggressiveness associated with the CYP1B1 4326C/G (Leu432Val) polymorphism: a meta-analysis of 2788 cases and 2968 controls. Asian J Androl, 2012, 14: 560–565.

Vainrib M, Golan M, Amir S, et al. HIF1A C1772T polymorphism leads to HIF-1 alpha mRNA overexpression in prostate cancer patients. Cancer Biol Ther, 2012, 13: 720–726.

Ye ZB, Ma T, Li H, et al. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol, 2007, 13: 1747–1751.

Eissa SA, Zaki SA, El-Maghraby SM, et al. Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst, 2005, 17: 51–55.

Cho D, Song H, Kim YM, et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res, 2000, 60: 2703–2709.

Farhat K, Hassen E, Bouzgarrou N, et al. Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine, 2008, 43: 132–137.

Liu Y, Lin N, Huang L, et al. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol, 2007, 26: 613–618.

Nikiteas N, Yannopoulos A, Chatzitheofylaktou A, et al. Heterozygosity for interleukin-18 -607A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res, 2007, 27: 3849–3853.

Campa D, Hung RJ, Mates D, et al. Lack of association between -251 T > A polymorphism of IL8 and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 2005, 14: 2457–2458.

Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev, 2006, 25: 417–434.

Kim J, Shao Y, Kim SY, et al. Hypoxia-induced IL-18 increases hypoxia-inducible factor-1alpha expression through a Rac1-dependent NF-kappaB pathway. Mol Biol Cell, 2008, 19: 433–444.

Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett, 2006, 103: 159–166.

Park H, Byun D, Kim TS, et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett, 2001, 79: 215–219.

Jiang DF, Liu WL, Lu YL, et al. Function of IL-18 in promoting metastasis of lung cancer. Chin J Cancer (Chinese), 2003, 25: 348–352.

Jung MK, Song HK, Kim KE, et al. IL-18 enhances the migration ability of murine melanoma cells through the generation of ROI and the MAPK pathway. Immunol Lett, 2006, 107: 125–130.

Li H, Ge C, Yan M, et al. Hypoxia-Inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/Integrin beta 1 signaling in human hepatocellular carcinoma. Hepatology, 2011, 54: 910–919.

Cornish J, Gillespie MT, Callon KE, et al. Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology, 2003, 144: 1194–1201.

Iwasaki T, Yamashita K, Tsujimura T, et al. Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. J Immunotherapy, 2002, 25: 52–60.

Gunel N, Cokun U, Sancak B, et al. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer, 2002, 95: 663–667.

Mantovani A, Savino B, Locati M, et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev, 2010, 21: 27–39.